Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT00001823	TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols	Phase	Date Added 1999-11-04	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05482516	TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers	Phase Phase 3	Date Added 2022-08-01	Location District of Columbia, United States New Jersey, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Atezolizumab, Bevacizumab, Avastin, Tecentriq	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06060704	TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.	Phase Phase 2	Date Added 2023-09-29	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02453620	TitleEntinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer	Phase Phase 1	Date Added 2015-05-25	Location California, United States Connecticut, United States Maryland, United States Pennsylvania, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Entinostat, Ipilimumab, Nivolumab, Opdivo, Yervoy	Tags MSS/ MMRp
NCT ID NCT04017650	TitleEncorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2019-07-12	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, encorafenib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT06923761	TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)	Phase Phase 1	Date Added 2025-04-11	Location Australia France Spain United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs	Tags MSI-H/ MMRd
NCT ID NCT04853017	TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)	Phase Phase 1	Date Added 2021-04-21	Location California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04730544	TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )	Phase Phase 2	Date Added 2021-01-29	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab	Tags MSI-H/ MMRd
NCT ID NCT06008119	TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2023-08-23	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05799443	TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer	Phase Phase 2	Date Added 2023-04-05	Location	Prior IO Allowed Yes	CRC-directed Yes	Status Not yet recruiting	Drugs cetuximab, Irinotecan Hydrochloride, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 171 to 180 of 299 entries